Case and Research Letters
Pityriasis Rosea-like Eruption Induced by Imatinib in a Patient With a Gastrointestinal Stromal Tumor
Erupción pitiriasis rosada-like inducida por imatinib en paciente con tumor del estroma gastrointestinal
S. Valenzuela-Ubiña
, I. Villegas-Romero, D. Jiménez-Gallo, M. Linares-Barrios
Corresponding author
Unidad de Gestión Clínica de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Puerta del Mar, Cádiz, Spain
Read
4107
Timeswas read the article
1594
Total PDF
2513
Total HTML
Share statistics
array:24 [ "pii" => "S1578219021002298" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.07.017" "estado" => "S300" "fechaPublicacion" => "2021-10-01" "aid" => "2600" "copyrightAnyo" => "2021" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2021;112:853-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0001731021000958" "issn" => "00017310" "doi" => "10.1016/j.ad.2020.01.010" "estado" => "S300" "fechaPublicacion" => "2021-10-01" "aid" => "2600" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2021;112:853-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta científico-clínica</span>" "titulo" => "Erupción pitiriasis rosada-<span class="elsevierStyleItalic">like</span> inducida por imatinib en paciente con tumor del estroma gastrointestinal" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "853" "paginaFinal" => "856" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Pityriasis Rosea-like Eruption Induced by Imatinib in a Patient With a Gastrointestinal Stromal Tumor" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2151 "Ancho" => 2508 "Tamanyo" => 539627 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A) Múltiples máculas rosadas ovaladas con collarete de descamación, distribuidas simétricamente en ambos flancos. B) Detalle de las lesiones localizadas en flanco derecho. C y D) Detalle del collarete de descamación presente en algunas lesiones.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "S. Valenzuela-Ubiña, I. Villegas-Romero, D. Jiménez-Gallo, M. Linares-Barrios" "autores" => array:4 [ 0 => array:2 [ "nombre" => "S." "apellidos" => "Valenzuela-Ubiña" ] 1 => array:2 [ "nombre" => "I." "apellidos" => "Villegas-Romero" ] 2 => array:2 [ "nombre" => "D." "apellidos" => "Jiménez-Gallo" ] 3 => array:2 [ "nombre" => "M." "apellidos" => "Linares-Barrios" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219021002298" "doi" => "10.1016/j.adengl.2021.07.017" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002298?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731021000958?idApp=UINPBA000044" "url" => "/00017310/0000011200000009/v1_202110020514/S0001731021000958/v1_202110020514/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S1578219021002304" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.07.018" "estado" => "S300" "fechaPublicacion" => "2021-10-01" "aid" => "2564" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2021;112:856-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Retroperitoneal Liposarcoma in a Woman With Neurofibromatosis Type 1" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "856" "paginaFinal" => "858" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Liposarcoma retroperitoneal en una paciente con una neurofibromatosis tipo 1" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1240 "Ancho" => 1674 "Tamanyo" => 105648 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Radiologic image. Computed tomography scan of the abdomen showing a large right retroperitoneal mass with a diameter of 11 cm displacing adjacent structures.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. Bou Boluda, J. Sabater Abad, E. Quecedo Estébanez, A.I. Jiménez Sánchez" "autores" => array:4 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Bou Boluda" ] 1 => array:2 [ "nombre" => "J." "apellidos" => "Sabater Abad" ] 2 => array:2 [ "nombre" => "E." "apellidos" => "Quecedo Estébanez" ] 3 => array:2 [ "nombre" => "A.I." "apellidos" => "Jiménez Sánchez" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002304?idApp=UINPBA000044" "url" => "/15782190/0000011200000009/v1_202110091021/S1578219021002304/v1_202110091021/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219021002365" "issn" => "15782190" "doi" => "10.1016/j.adengl.2021.07.024" "estado" => "S300" "fechaPublicacion" => "2021-10-01" "aid" => "2601" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2021;112:851-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Granulomatous Dactylitis: An Unusual Finding in Sarcoidosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "851" "paginaFinal" => "853" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Dactilitis granulomatosa como manifestación inusual de la sarcoidosis" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 680 "Ancho" => 905 "Tamanyo" => 178504 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Histologic study of the facial skin lesions with granulomas in the middle and deep dermis, with no central necrosis or lymphocytic corona.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "I. García Morales, E. Sánchez García, A. Crespo Cruz, J. Escudero" "autores" => array:4 [ 0 => array:2 [ "nombre" => "I." "apellidos" => "García Morales" ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Sánchez García" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "Crespo Cruz" ] 3 => array:2 [ "nombre" => "J." "apellidos" => "Escudero" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S000173102100096X" "doi" => "10.1016/j.ad.2020.01.011" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173102100096X?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002365?idApp=UINPBA000044" "url" => "/15782190/0000011200000009/v1_202110091021/S1578219021002365/v1_202110091021/en/main.assets" ] "en" => array:16 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Pityriasis Rosea-like Eruption Induced by Imatinib in a Patient With a Gastrointestinal Stromal Tumor" "tieneTextoCompleto" => true "saludo" => "To the Editor," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "853" "paginaFinal" => "856" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "S. Valenzuela-Ubiña, I. Villegas-Romero, D. Jiménez-Gallo, M. Linares-Barrios" "autores" => array:4 [ 0 => array:4 [ "nombre" => "S." "apellidos" => "Valenzuela-Ubiña" "email" => array:1 [ 0 => "sandra.vzla@hotmail.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "I." "apellidos" => "Villegas-Romero" ] 2 => array:2 [ "nombre" => "D." "apellidos" => "Jiménez-Gallo" ] 3 => array:2 [ "nombre" => "M." "apellidos" => "Linares-Barrios" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Unidad de Gestión Clínica de Dermatología Médico-Quirúrgica y Venereología, Hospital Universitario Puerta del Mar, Cádiz, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Erupción pitiriasis rosada-<span class="elsevierStyleItalic">like</span> inducida por imatinib en paciente con tumor del estroma gastrointestinal" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2152 "Ancho" => 2508 "Tamanyo" => 1364806 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">A, Histologic image highlighting a superficial dermal infiltrate. B, Higher-magnification view showing spongiotic dermatitis with a perivascular infiltrate and focal parakeratosis. C, Detail of predominantly lymphocytic perivascular infiltrate. D, Detail of spongiotic dermatitis with a focus of parakeratosis.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Imatinib is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GISTs), and metastatic dermatofibrosarcoma protuberans.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–5</span></a> It works by competitively inhibiting the adenosine triphosphate binding site, preventing phosphorylation of the proteins BCR-ABL and c-kit and platelet-derived growth factor receptor (PDGFR).<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,5–8</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">A 78-year-old woman with a metastatic GIST under treatment with imatinib 400 mg/d for a month and a half presented with a slightly pruritic abdominal skin rash of 1 week’s duration. Physical examination showed oval pink macules with collarette scaling symmetrically distributed on both flanks (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). The laboratory work-up was normal, including negative serology for treponema. Histology showed spongiotic dermatitis with a predominantly lymphocytic perivascular infiltrate with occasional eosinophils and focal parakeratosis; these findings were consistent with pityriasis rosea (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). Considering the histologic findings and recent history of imatinib initiation, the patient was diagnosed with pityriasis rosea–like drug eruption induced by imatinib.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Imatinib was discontinued and treatment started with topical betamethasone and oral loratadine 20 mg every 12 hours. The lesions resolved completely within 2 weeks. Considering the favorable outcome, the patient was restarted on imatinib at a dosage of 100 mg every 12 hours, which was progressively increased to reach 400 mg/d at 3 weeks. No new skin lesions appeared.</p><p id="par0020" class="elsevierStylePara elsevierViewall">The adverse effects of imatinib are classified as hematologic or nonhematologic.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,8</span></a> The most common nonhematologic responses are cutaneous, with a prevalence of 7% to 88.9% depending on the series,<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,4,8</span></a> They are usually mild to moderate, dose dependent, and do not require permanent withdrawal of imatinib.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,4,6–9</span></a> They can be treated with oral antihistamines or topical or low-dose oral corticosteroids.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,8</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">The most common skin reactions are nonspecific, but there have been reports of generalized acute exanthematous pustulosis, Stevens-Johnson syndrome, mycosis fungoides–like lesions, psoriasiform eruptions, erosive oral lichen planus, exfoliative dermatitis, and neutrophilic dermatosis.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–4,6–8</span></a> Pityriasis rosea–like drug eruptions are uncommon, with just a few cases reported to date.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Pityriasis rosea presents as asymptomatic or mildly pruritic erythematous macules with fine peripheral collarette scaling that resolve spontaneously with several weeks.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9,10</span></a> Its etiology is unknown, but an association with infection by herpesvirus 6 and 7 has been postulated.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,9,10</span></a> There have also been reports of pityriasis rosea–like drug eruptions induced by omeprazole, metronidazole, terbinafine, captopril, D-penicillamine, isotretinoin, nortriptyline, gold salts, lithium, anti-tumor necrosis factor, and imatinib.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3,6,9</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">The first case of pityriasis rosea–like eruption induced by imatinib was reported by Konstantopoulos et al.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> All the cases described to date have involved typical pityriasis rosea lesions on the trunk and extremities.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–3,6,9,10</span></a> Similarly to in our case, histology shows a superficial perivascular lymphocytic infiltrate with occasional eosinophils, spongiosis, focal parakeratosis, and necrotic keratinocytes.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–3,6,10</span></a> There have also been reports of acanthosis and red blood cell extravasation.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–3</span></a> We did not perform immunohistochemical staining for CD4/CD8 (this could show a predominance of CD8<span class="elsevierStyleSup">+</span> lymphocytes in the epidermis and CD4<span class="elsevierStyleSup">+</span> lymphocytes in the dermis) or observe necrotic keratinocytes or extravasation of red blood cells. These findings would support a causative role for imatinib. Nonetheless, the histology findings, time from initiation of imatinib to the onset of the symptoms (month and a half), and rapid resolution of the clinical manifestations (2 weeks) following discontinuation of the drug all support the diagnosis of imatinib-induced pityriasis rosacea–like drug eruption. In addition, the time frames are similar to those described elsewhere.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Pityriasis rosea–like eruptions induced by imatinib tend to resolve when the drug is discontinued, but they can reappear following reinstatement at high doses (300-400 mg/d).<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–3,6</span></a> Reappearance of lesions supports the diagnosis of a drug-induced eruption. The association between prevalence and dose suggests that imatinib-induced pityriasis rosea–like eruptions are caused by the drug's inhibition of c-kit and/or PDGFR, which are expressed in keratinocytes, melanocytes, mast cells, and sweat glands.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,4,6–8</span></a> In our case, the patient’s rash resolved within 2 weeks of stopping imatinib, and it did not return when treatment was restored. As proposed by Cho et al.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a>, this might be because of the progressive increase in dosage (from 100 mg/d every 12 hours to 400 mg/d over a 3-week period free of lesions).</p><p id="par0045" class="elsevierStylePara elsevierViewall">We have presented, to our knowledge, the first case of pityriasis rosea–like drug eruption induced by imatinib in a patient with a GIST. All the cases to date have been described in patients with chronic myeloid leukemia (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Pityriasis rosea–like drug eruptions are uncommon, generally of a mild to moderate intensity, and resolve on discontinuation of the causative drug. To prevent recurrence, imatinib should be reintroduced progressively or, in the case of GIST, replaced with sunitinib, for which pityriasis rosea–like drug eruptions have not been described.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicts of Interest</span><p id="par0050" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflicts of Interest" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Valenzuela-Ubiña S, Villegas-Romero I, Jiménez-Gallo D, Linares-Barrios M. Erupción pitiriasis rosada-<span class="elsevierStyleItalic">like</span> inducida por imatinib en paciente con tumor del estroma gastrointestinal. Actas Dermosifiliogr. 2021;112:853–856.</p>" ] ] "multimedia" => array:3 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2151 "Ancho" => 2508 "Tamanyo" => 539627 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A, Multiple oval pink macules with collarette scaling, symmetrically distributed on both flanks. B, Detail of lesions on right flanks. C and D, Detail of collarette scaling observed in several lesions.</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2152 "Ancho" => 2508 "Tamanyo" => 1364806 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">A, Histologic image highlighting a superficial dermal infiltrate. B, Higher-magnification view showing spongiotic dermatitis with a perivascular infiltrate and focal parakeratosis. C, Detail of predominantly lymphocytic perivascular infiltrate. D, Detail of spongiotic dermatitis with a focus of parakeratosis.</p>" ] ] 2 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0015" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Abbreviations: CML, chronic myeloid leukemia; GIST, gastrointestinal stromal tumor.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Underlying Disease \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Sex, Age, y \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Treatment Duration, Imatinib Dosage \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Remission of Lesions After Discontinuation, Treatment \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Reintroduction of Imatinib \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Actions \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Cho et al., <span class="elsevierStyleItalic">Ann Dermatol. 2011</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CLM \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Female, 74 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 mo, 400 mg/d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 wk, oral antihistamine and topical corticosteroid \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">400  mg/d with reappearance of lesions after 7 d, \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Replacement with nilotinib, no recurrence of lesions \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pasmatzi et al., <span class="elsevierStyleItalic">Acta Derm Venereol. 2003</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CML \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Female, 51 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 mo, alternating between 200 and 300 mg/d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 wk, low-dose oral corticosteroids \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">300  mg/d with reappearance of lesions after 6 d, \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Imatinib (dosage not specified) + 4 mg oral methylprednisolone on alternating days, remission of lesions after 4 mo \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Verma et al., <span class="elsevierStyleItalic">Indian J Dermatol. 2014</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CML \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Male, 24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 mo, 400 mg/d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 wk, no treatment \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100 mg/d, reappearance of lesions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Progressive increase in imatinib dosage to 400 mg/d + topical corticosteroid and oral antihistamine, control of lesions \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Konstantopoulos et al., <span class="elsevierStyleItalic">Dermatology. 2002</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CML \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Female, 42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 mo, 400 mg/d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Resolution not specified, oral antihistamine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Imatinib not reintroduced \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Replaced by ridarubicin + cytarabine + oral corticosteroid, patient died \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Brazzelli et al., <span class="elsevierStyleItalic">J Am Acad Dermatol. 2005</span> (3 cases) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">1)</span> CML \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">1)</span> Male, 58 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">1</span>) 1 mo, 400 mg/d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1) 2 wk, oral antihistamine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1) 400 mg/d, reappearance of lesions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">1</span>) Imatinib 400 mg/d, occasional lesions, no treatment required \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">2)</span> CML \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">2)</span> Male, 58 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">2</span>) 1 mo, 400 mg/d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">2</span>) Time not specified, antihistamine and oral corticosteroids \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2) 300 mg/d, reappearance of lesions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">2</span>) Imatinib 400 mg/d, occasional lesions, no treatment required \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">3)</span> CML \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">3)</span> Male, 35 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">3</span>) 1 mo, 400 mg/d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">3</span>) Time not specified, antihistamine and oral corticosteroids \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">3)</span> 100 mg/d for 1 wk followed by 200 mg/d, reappearance of lesions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">3)</span><span class="elsevierStyleBold">i</span>matinib 400 mg/d + low-dose oral corticosteroid, control of lesions \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Current case \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">GIST \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Female, 78 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.5 mo, 400 mg/d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 wk, topical corticosteroid and oral antihistamine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100 mg/12 h, no reappearance of lesions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Progressive increase in imatinib dosage to 400 mg/d, no reappearance of lesions \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2716699.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Cases of Imatinib-Induced Pityriasis Rosacea–like Drug Eruptions in the Literature.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pityriasis rosea-like drug eruption induced by imatinib mesylate (Gleevec)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A.Y. Cho" 1 => "D.H. Kim" 2 => "M. Im" 3 => "Y. Lee" 4 => "Y.J. Seo" 5 => "J.H. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5021/ad.2011.23.S3.S360" "Revista" => array:7 [ "tituloSerie" => "Ann Dermatol." "fecha" => "2011" "volumen" => "23" "numero" => "Supple 3" "paginaInicial" => "S360" "paginaFinal" => "363" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22346278" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "E. Pasmatzi" 1 => "A. Monastirli" 2 => "P. Matsouka" 3 => "D. Tsambaos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/00015550310012593" "Revista" => array:6 [ "tituloSerie" => "Acta Derm Venereol." "fecha" => "2003" "volumen" => "83" "paginaInicial" => "391" "paginaFinal" => "392" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14609118" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Imatinib mesylate-induced cutaneous rash masquerading as pitiriasis rosea of Gibert" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "P. Verma" 1 => "A. Singal" 2 => "S. Sharma" ] ] ] ] ] "host" => array:2 [ 0 => array:2 [ "doi" => "10.4103/0019-5154.131433" "Revista" => array:6 [ "tituloSerie" => "Indian J Dermatol." "fecha" => "2014" "volumen" => "59" "paginaInicial" => "311" "paginaFinal" => "312" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24891677" "web" => "Medline" ] ] ] ] 1 => array:2 [ "doi" => "10.4103/0019-5154.131433" "WWW" => array:1 [ "link" => "http://www.e-ijd.org/text.asp?2014/59/3/311/131433" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Skin lesions in patients treated with imatinib mesylate: A 5-year prospective study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G. Paolino" 1 => "D. Didona" 2 => "R. Clerico" 3 => "P. Corsetti" 4 => "M. Ambrifi" 5 => "U. Bottoni" ] ] ] ] ] "host" => array:2 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cutis." "fecha" => "2016" "volumen" => "97" "paginaInicial" => "E12" "paginaFinal" => "16" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27416091" "web" => "Medline" ] ] ] ] 1 => array:1 [ "WWW" => array:1 [ "link" => "http://www.jpgmonline.com/text.asp?2017/63/1/55/194227" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Dagher" 1 => "M. Cohen" 2 => "G. Williams" 3 => "M. Rothmann" 4 => "J. Gobburu" 5 => "G. Robbie" ] ] ] ] ] "host" => array:2 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Cancer Res." "fecha" => "2002" "volumen" => "8" "paginaInicial" => "3034" "paginaFinal" => "3038" ] ] 1 => array:1 [ "WWW" => array:1 [ "link" => "http://clincancerres.aacrjournals.org/content/8/10/3034.long" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Brazzelli" 1 => "F. Prestinari" 2 => "E. Roveda" 3 => "T. Barbagallo" 4 => "E. Bellani" 5 => "C. Vassallo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2004.10.888" "Revista" => array:7 [ "tituloSerie" => "J Am Acad Dermatol." "fecha" => "2005" "volumen" => "53" "numero" => "5 Suppl 1" "paginaInicial" => "S240" "paginaFinal" => "243" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16227099" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Valeyrie" 1 => "S. Bustuji-Garin" 2 => "J. Revuz" 3 => "N. Bachot" 4 => "J. Wechsler" 5 => "P. Berthaud" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1067/mjd.2003.44" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol." "fecha" => "2003" "volumen" => "48" "paginaInicial" => "201" "paginaFinal" => "206" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12582389" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A 6-year follow up" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "E. Dervis" 1 => "M. Ayer" 2 => "S. Akin Belli" 3 => "S.G. Barut" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1684/ejd.2015.2684" "Revista" => array:6 [ "tituloSerie" => "Eur J Dermatol." "fecha" => "2016" "volumen" => "26" "paginaInicial" => "133" "paginaFinal" => "137" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26679005" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pityriasis rosea associated with Imatinib (STI571, Gleevec)" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "K. Konstantopoulos" 1 => "A. Papadogianni" 2 => "M. Dimopoulou" 3 => "C. Kourelis" 4 => "J. Meletis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000063900" "Revista" => array:6 [ "tituloSerie" => "Dermatology." "fecha" => "2002" "volumen" => "205" "paginaInicial" => "172" "paginaFinal" => "173" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12218236" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pityriasis rosea-like drug eruption due to nortriptyline in a patient with vulvodynia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "H.K. Bangash" 1 => "T. Finch" 2 => "V. Petronic-Rosic" 3 => "A. Sethi" 4 => "E. Abramsohn" 5 => "S.T. Lindau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/LGT.0b013e31825d7c5f" "Revista" => array:6 [ "tituloSerie" => "J Low Genit Tract Dis." "fecha" => "2013" "volumen" => "17" "paginaInicial" => "226" "paginaFinal" => "229" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23343697" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000011200000009/v1_202110091021/S1578219021002298/v1_202110091021/en/main.assets" "Apartado" => array:4 [ "identificador" => "6157" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Case and Research Letters" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011200000009/v1_202110091021/S1578219021002298/v1_202110091021/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219021002298?idApp=UINPBA000044" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 11 | 8 | 19 |
| 2024 October | 82 | 69 | 151 |
| 2024 September | 82 | 43 | 125 |
| 2024 August | 100 | 67 | 167 |
| 2024 July | 90 | 47 | 137 |
| 2024 June | 86 | 36 | 122 |
| 2024 May | 68 | 42 | 110 |
| 2024 April | 60 | 32 | 92 |
| 2024 March | 61 | 38 | 99 |
| 2024 February | 63 | 36 | 99 |
| 2024 January | 66 | 41 | 107 |
| 2023 December | 72 | 22 | 94 |
| 2023 November | 94 | 29 | 123 |
| 2023 October | 75 | 23 | 98 |
| 2023 September | 78 | 30 | 108 |
| 2023 August | 51 | 11 | 62 |
| 2023 July | 52 | 31 | 83 |
| 2023 June | 61 | 32 | 93 |
| 2023 May | 70 | 28 | 98 |
| 2023 April | 52 | 23 | 75 |
| 2023 March | 79 | 38 | 117 |
| 2023 February | 50 | 33 | 83 |
| 2023 January | 44 | 36 | 80 |
| 2022 December | 53 | 56 | 109 |
| 2022 November | 35 | 35 | 70 |
| 2022 October | 33 | 29 | 62 |
| 2022 September | 34 | 45 | 79 |
| 2022 August | 47 | 42 | 89 |
| 2022 July | 31 | 36 | 67 |
| 2022 June | 35 | 29 | 64 |
| 2022 May | 71 | 47 | 118 |
| 2022 April | 63 | 37 | 100 |
| 2022 March | 83 | 62 | 145 |
| 2022 February | 85 | 33 | 118 |
| 2022 January | 63 | 35 | 98 |
| 2021 December | 68 | 48 | 116 |
| 2021 November | 62 | 58 | 120 |
| 2021 October | 113 | 84 | 197 |
| 2021 September | 63 | 54 | 117 |
| 2021 August | 24 | 67 | 91 |
| 2021 July | 3 | 2 | 5 |
Show all
